The Children’s Tumor Foundation (CTF) has announced that Brigid Garelik, MD, MPH, has been appointed Chief Medical Officer, overseeing the Foundation’s research and clinical initiatives. In this role, Dr. Garelik will set direction for the Foundation’s innovative R&D programs, developing effective clinical and preclinical strategies in order to deliver treatments to patients. She will also direct the Foundation’s educational programs in support of NF healthcare professionals, growing the NF field, and R&D related patient engagement. She will report to the President of the Children’s Tumor Foundation, Annette Bakker, PhD.
Dr. Garelik is an accomplished pediatric oncologist, scientist, and senior level pharma/biotech executive with extensive experience in the healthcare landscape spanning basic research, patient care, and global drug development. She brings to the role broad therapeutic expertise leading teams and in developing novel therapies in small molecules, biologics, and cell and gene therapy, from the preclinical stage to successful approvals and product launch to market. Her prior experience includes 10 plus years as a physician scientist at a large academic medical center followed by 15+ years in oncology clinical development in both global pharmaceutical corporations and biotechnology organizations.
The Children’s Tumor Foundation is the world’s leading organization dedicated to funding and driving innovative research that will result in effective treatments for the millions of people worldwide living with NF, a group of genetic conditions that cause tumors to grow on nerves throughout the body. One in every 2,000 people is born with some type of neurofibromatosis or schwannomatosis, which may lead to blindness, deafness, bone abnormalities, disfigurement, learning disabilities, disabling pain, or cancer. NF affects all populations equally, and while there is one approved treatment for a subset of NF patients, the vast majority have no treatment options, and there is no cure yet. The Children’s Tumor Foundation mission of driving research, expanding knowledge, and advancing care for the NF community fosters its vision of one day ending NF.
For more information, please visit: ctf.org.
For inquiries, please contact: info@ctf.org.
